Comerica Bank’s Terns Pharmaceuticals TERN Stock Holding History

Comerica Bank’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$4.24K	Buy	+105	New	+$2.43K	﹤0.01%	3432

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CLGM

Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

Comerica Bank's TERN Position: Q4 2025 in Review

Comerica Bank opened a new position in Terns Pharmaceuticals (TERN) in Q4 2025: 105 shares worth $4.24K. The stake represents ﹤0.01% of the portfolio and ranks #3432 among its holdings.

248 funds tracked by Wall St. Rank hold TERN as of Q4 2025.

Comerica Bank held 105 shares of Terns Pharmaceuticals worth $4.24K as of Q4 2025.
Terns Pharmaceuticals was a new Comerica Bank position in Q4 2025.
Terns Pharmaceuticals made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3432 holding.
248 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.